SAN FRANCISCO, May 24, 2017 — Xarelto patients who suffered internal bleeding and other life-threatening complications allegedly related to use of the medication continue to file lawsuits in courts throughout the U.S. According to a May 3rd filing with the U.S. Securities and Exchange Commission, Johnson & Johnson and Bayer AG have been named defendants in at least 18,900 Xarelto lawsuits, most of which are pending in a federal multi-district litigation now underway in the U.S. District Court, Eastern District of Louisiana. Xarelto litigations have also been established in state courts in Pennsylvania, Delaware, California and Missouri, while class action lawsuits have been filed in Canada.
Scovern Law is representing a number of Xarelto lawsuit plaintiffs, and we continue to receive inquiries from others who were allegedly harmed by this blood thinner. “We are not surprised that the litigation surrounding this medication continues to grow,” says Susanne Scovern, founder of Scovern Law, a nationwide law firm representing victims of defective medical devices and drugs. The firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.
Xarelto Litigation
Xarelto is an oral anticoagulant jointly marketed by Bayer and Johnson & Johnson. The blood thinner was approved by the U.S. Food & Drug Administration (FDA) in 2011, and is currently indicated for the prevention of strokes in atrial fibrillation patients; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee implant surgery.
Xarelto plaintiffs allege that Bayer and Johnson & Johnson failed to provide adequate warnings regarding uncontrollable bleeding that may occur with its use, and wrongly promoted the blood thinner as a superior alternative to warfarin. Among other things, plaintiffs note that bleeding associated with warfarin can be reversed via the administration of vitamin K. However, there is currently no approved antidote to stop Xarelto bleeding events.
The multi-district litigation underway in the Eastern District of Louisiana houses at least 16,670 Xarelto lawsuits. The proceeding is scheduled to convene its second bellwether trial on May 30th in New Orleans. Verdicts in these trials may provide insight into how juries could rule in similar Xarelto claims. Johnson & Johnson and Bayer prevailed in the first Xarelto trial, which concluded earlier this month. (In Re: Xarelto Products Liability Litigation, No. 2592).
Xarelto patients who allegedly experienced bleeding-related complications may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit the Scovern Law website, or call 888-725-1890 to arrange for a free, no obligation case review.